BiotechTube

Reproxalap Ophthalmic Solution (0.25%) QID + Vehicle Ophthalmic Solution QID + Reproxalap Ophthalmic Solution (0.25%) QID to BID + Vehicle Ophthalmic Solution QID to BID

Phase 3Completed
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dry Eye

Conditions

Dry Eye

Trial Timeline

Apr 16, 2019 → Oct 4, 2019

NCT ID
NCT03879863

About Reproxalap Ophthalmic Solution (0.25%) QID + Vehicle Ophthalmic Solution QID + Reproxalap Ophthalmic Solution (0.25%) QID to BID + Vehicle Ophthalmic Solution QID to BID

Reproxalap Ophthalmic Solution (0.25%) QID + Vehicle Ophthalmic Solution QID + Reproxalap Ophthalmic Solution (0.25%) QID to BID + Vehicle Ophthalmic Solution QID to BID is a phase 3 stage product being developed by Aldeyra Therapeutics for Dry Eye. The current trial status is completed. This product is registered under clinical trial identifier NCT03879863. Target conditions include Dry Eye.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT03879863Phase 3Completed

Competing Products

20 competing products in Dry Eye

See all competitors
ProductCompanyStageHype Score
Cyclosporine Ophthalmic 0.05% Ophthalmic EmulsionSight SciencesPre-clinical
15
OK-101 + PlaceboOKYO PharmaPhase 2
44
ISV 101Sun PharmaceuticalPhase 2
52
CequaTM (Cyclosporine 0.09%) ophthalmic solutionSun PharmaceuticalApproved
85
0.09% cyclosporine A ophthalmic solutionSun PharmaceuticalPre-clinical
23
Cyclosporine + Artificial tearSun PharmaceuticalApproved
85
nanomicellular cyclosporine 0.09% + LifitegrastSun PharmaceuticalApproved
85
Cyclosporine 0.09% Ophthalmic SolutionSun PharmaceuticalApproved
85
Investigational Lubricating Eye Drop in a Novelia® bottle + Blink® Tears eye DropsJohnson & JohnsonPhase 2
52
diquafosol ophthalmic solution + 0.1% sodium hyaluronate ophthalmic solution.Santen PharmaceuticalPre-clinical
23
Diquafosol sodium 3% + Sodium hyaluronate 0.1%Santen PharmaceuticalPhase 2
52
3% DE-089 ophthalmic solution + 0.1% sodium hyaluronate ophthalmic solutionSanten PharmaceuticalPhase 3
77
Placebo ophthalmic solution and 3% DE-089 ophthalmic solutionSanten PharmaceuticalPhase 1
33
DE-089 ophthalmic solution + DE-089 ophthalmic solution + Placebo ophthalmic solutionSanten PharmaceuticalPhase 2
52
SHR8028 eye drops + Vehicle eye drops.Jiangsu Hengrui MedicinePhase 3
77
SHR8058 eye drops + saline eye drops.Jiangsu Hengrui MedicinePhase 3
77
ABBV-444 + REFRESH OPTIVE UDAbbViePhase 3
77
AGN-242428 + AGN-231868 + Lifitegrast 5% Ophthalmic SolutionAbbViePhase 1/2
41
ABBV-444AbbViePhase 3
77
Next Generation Emulsion Preservative Free Eye Drops (NGE-UD)AbbViePre-clinical
23

Other Products from Aldeyra Therapeutics

Reproxalap Ophthalmic Solution (0.25%) + Reproxalap Ophthalmic Solution (0.5%) + Vehicle Ophthalmic SolutionPhase 3
69
Reproxalap Ophthalmic Solution (0.25%) + Vehicle Ophthalmic SolutionPhase 3
69
Reproxalap Ophthalmic Solution (0.25%) + Vehicle Ophthalmic SolutionPhase 3
69
ADX-2191 (intravitreal methotrexate 0.8%)Phase 3
69
Reproxalap Ophthalmic Solution (0.25%) + Placebo Comparator + Reproxalap Ophthalmic Solution (0.25%) + Placebo ComparatorPhase 3
69